RATIONALE: There is a focus on developing D3 receptor antagonists as cocaine addiction treatments. OBJECTIVE: We investigated the effects of a novel selective D3 receptor antagonist, SR 21502, on cocaine reward, cocaine-seeking, food reward, spontaneous locomotor activity and cocaine-induced locomotor activity in rats. METHODS: In Experiment 1, rats were trained to self-administer cocaine under a progressive ratio (PR) schedule of reinforcement and tested with vehicle or one of three doses of SR 21502. In Experiment 2, animals were trained to self-administer cocaine under a fixed ratio schedule of reinforcement followed by extinction of the response. Then, animals were tested with vehicle or one of the SR 21502 doses on cue-induced reinstatement of responding. In Experiment 3, animals were trained to lever press for food under a PR schedule and tested with vehicle or one dose of the compound. In Experiments 4 and 5, in separate groups of animals, the vehicle and three doses of SR 21502 were tested on spontaneous or cocaine (10 mg/kg, IP)-induced locomotor activity, respectively. RESULTS: SR 21502 produced significant, dose-related (3.75, 7.5 and 15 mg/kg) reductions in breakpoint for cocaine self-administration, cue-induced reinstatement (3.75, 7.5 and 15 mg/kg) and cocaine-induced locomotor activity (3.75, 7.5 and 15 mg/kg) but failed to reduce food self-administration and spontaneous locomotor activity. CONCLUSIONS: SR 21502 decreases cocaine reward, cocaine-seeking and locomotor activity at doses that have no effect on food reward or spontaneous locomotor activity. These data suggest SR 21502 may selectively inhibit cocaine's rewarding, incentive motivational and stimulant effects.
RATIONALE: There is a focus on developing D3 receptor antagonists as cocaine addiction treatments. OBJECTIVE: We investigated the effects of a novel selective D3 receptor antagonist, SR 21502, on cocaine reward, cocaine-seeking, food reward, spontaneous locomotor activity and cocaine-induced locomotor activity in rats. METHODS: In Experiment 1, rats were trained to self-administer cocaine under a progressive ratio (PR) schedule of reinforcement and tested with vehicle or one of three doses of SR 21502. In Experiment 2, animals were trained to self-administer cocaine under a fixed ratio schedule of reinforcement followed by extinction of the response. Then, animals were tested with vehicle or one of the SR 21502 doses on cue-induced reinstatement of responding. In Experiment 3, animals were trained to lever press for food under a PR schedule and tested with vehicle or one dose of the compound. In Experiments 4 and 5, in separate groups of animals, the vehicle and three doses of SR 21502 were tested on spontaneous or cocaine (10 mg/kg, IP)-induced locomotor activity, respectively. RESULTS:SR 21502 produced significant, dose-related (3.75, 7.5 and 15 mg/kg) reductions in breakpoint for cocaine self-administration, cue-induced reinstatement (3.75, 7.5 and 15 mg/kg) and cocaine-induced locomotor activity (3.75, 7.5 and 15 mg/kg) but failed to reduce food self-administration and spontaneous locomotor activity. CONCLUSIONS:SR 21502 decreases cocaine reward, cocaine-seeking and locomotor activity at doses that have no effect on food reward or spontaneous locomotor activity. These data suggest SR 21502 may selectively inhibit cocaine's rewarding, incentive motivational and stimulant effects.
Authors: Zheng-Xiong Xi; Amy Hauck Newman; Jeremy G Gilbert; Arlene C Pak; Xiao-Qing Peng; Charles R Ashby; Leah Gitajn; Eliot L Gardner Journal: Neuropsychopharmacology Date: 2005-10-05 Impact factor: 7.853
Authors: Fabrizio Micheli; Giorgio Bonanomi; Frank E Blaney; Simone Braggio; Anna Maria Capelli; Anna Checchia; Ornella Curcuruto; Federica Damiani; Romano Di Fabio; Daniele Donati; Gabriella Gentile; Andy Gribble; Dieter Hamprecht; Giovanna Tedesco; Silvia Terreni; Luca Tarsi; Andrew Lightfoot; Geoff Stemp; Gregor Macdonald; Alex Smith; Michela Pecoraro; Marcella Petrone; Ornella Perini; Jacqui Piner; Tino Rossi; Angela Worby; Maria Pilla; Enzo Valerio; Cristiana Griffante; Manolo Mugnaini; Martyn Wood; Claire Scott; Michela Andreoli; Laurent Lacroix; Adam Schwarz; Alessandro Gozzi; Angelo Bifone; Charles R Ashby; Jim J Hagan; Christian Heidbreder Journal: J Med Chem Date: 2007-09-15 Impact factor: 7.446
Authors: Gregor J Macdonald; Clive L Branch; Michael S Hadley; Christopher N Johnson; David J Nash; Alexander B Smith; Geoffrey Stemp; Kevin M Thewlis; Antonio K K Vong; Nigel E Austin; Phillip Jeffrey; Kim Y Winborn; Izzy Boyfield; Jim J Hagan; Derek N Middlemiss; Charlie Reavill; Graham J Riley; Jeannette M Watson; Martyn Wood; Steve G Parker; Charles R Ashby Journal: J Med Chem Date: 2003-11-06 Impact factor: 7.446
Authors: Chloe J Jordan; Bree A Humburg; Eric B Thorndike; Anver Basha Shaik; Zheng-Xiong Xi; Michael H Baumann; Amy Hauck Newman; Charles W Schindler Journal: J Pharmacol Exp Ther Date: 2019-09-27 Impact factor: 4.030
Authors: Callum Hicks; Peng Huang; Linnet Ramos; Sunil U Nayak; Yohanka Caro; Allen B Reitz; Garry R Smith; David Y-W Lee; Scott M Rawls; Lee-Yuan Liu-Chen Journal: ACS Chem Neurosci Date: 2018-04-06 Impact factor: 4.418
Authors: Hazem E Hassan; Deanna Kelly; Moshe Honick; Sagar Shukla; Ahmed Ibrahim; David A Gorelick; Matthew Glassman; Robert P McMahon; Heidi J Wehring; Ann Marie Kearns; Stephanie Feldman; Mingming Yu; Ken Bauer; Jia Bei Wang Journal: J Clin Pharmacol Date: 2016-08-04 Impact factor: 3.126